The serotonin 5-HT5 receptor represents one of the most enigmatic members of the serotonin receptor family, with the least understood physiological functions. These inhibitory GPCRs are expressed in brain regions critical for cognition, mood, and sleep regulation. Despite their discovery decades ago, 5-HT5 receptors have remained relatively understudied compared to other serotonin receptor subtypes, making them an intriguing target for future therapeutic development in neurological and psychiatric disorders.
| Property |
Value |
| Category |
Serotonin Receptor Neurons |
| Primary Receptor |
5-HT5A (encoded by HTR5A gene), 5-HT5B (encoded by HTR5B gene) |
| Gene Symbol |
HTR5A, HTR5B |
| Signal Transduction |
Gi/o protein-coupled inhibition of adenylate cyclase |
| Brain Regions |
Cortex, hippocampus, cerebellum, thalamus, hypothalamus |
| Expression Pattern |
Neuronal (primarily postsynaptic), some presynaptic |
¶ Receptor Genes and Structure
The 5-HT5 receptor family consists of two subtypes:
| Subtype |
Gene |
Chromosome |
Protein Length |
| 5-HT5A |
HTR5A |
7q36.3 |
357 amino acids |
| 5-HT5B |
HTR5B |
2q37.1 |
370 amino acids |
Structural Features:
- Seven transmembrane domains typical of Class A GPCRs
- Conserved DRY motif at intracellular loop 3
- Disulfide bond between Cys residues in extracellular loops
- N-linked glycosylation sites in N-terminal domain
5-HT5 receptors couple primarily to Gi/o proteins:
- Inhibition of adenylate cyclase → decreased cAMP
- Activation of MAPK pathways (ERK1/2)
- Modulation of ion channels (inhibition of voltage-gated Ca2+ channels)
- Beta-arrestin recruitment (biased signaling)
¶ Ligand Binding
- Endogenous ligand: Serotonin (5-HT)
- High affinity for serotonin (nanomolar range)
- Limited selective ligands available due to undercharacterization
5-HT5 receptor expression in the human brain:
Cerebral Cortex:
- Layer I-V pyramidal neurons
- GABAergic interneurons
- Highest cortical density in frontal and parietal lobes
Hippocampus:
- CA1 pyramidal neurons
- Dentate gyrus granule cells
- Interneurons in strata radiatum and lacunosum-moleculare
Cerebellum:
- Purkinje cells
- Granule cell layer
- Deep cerebellar nuclei
Other Regions:
- Thalamus (intralaminar nuclei)
- Hypothalamus (paraventricular nucleus)
- Basal ganglia (caudate, putamen)
- Postsynaptic: Primary location on dendritic shafts and spines
- Presynaptic: Lower density on axon terminals
- Somatic: Moderate expression on cell bodies
- Non-neuronal: Limited expression on astrocytes
5-HT5 receptors mediate inhibitory neurotransmission:
- Serotonin binding activates Gi/o protein
- Adenylate cyclase inhibition reduces cAMP
- Reduced PKA activity affects downstream targets
- Ion channel modulation hyperpolarizes neurons
- Reduced neuronal excitability results
| Brain Region |
Effect |
Functional Outcome |
| Cortex |
Pyramidal neuron inhibition |
Balanced excitation/inhibition |
| Hippocampus |
LTP modulation |
Memory consolidation |
| Cerebellum |
Purkinje cell regulation |
Motor coordination |
| Thalamus |
Sensory gating |
Arousal modulation |
5-HT5 receptors play important roles in sleep architecture:
- Sleep regulation: 5-HT5A modulates REM and non-REM sleep
- Circadian rhythm: Interaction with suprachiasmatic nucleus
- Insomnia: Potential therapeutic target
- Sleep homeostasis: Regulation of sleep pressure
- 5-HT5 receptors located on cerebral vasculature
- Vascular tone modulation
- Pain signaling in trigeminal pathway
- Therapeutic potential for acute migraine
- Memory function: 5-HT5A in hippocampal plasticity
- Learning: Potential role in cognitive processing
- Alzheimer's disease: Altered expression in AD brains
- Therapeutic target: Cognitive enhancement
¶ Depression and Anxiety
- 5-HT system widely implicated in mood disorders
- Limited data on 5-HT5 specifically
- Interaction with other 5-HT receptors
- Novel antidepressant potential
- 5-HT5A binding altered in schizophrenia
- Cognitive symptoms may involve 5-HT5
- Interaction with dopaminergic system
- Research ongoing
¶ Research and Therapeutic Development
¶ Selective Ligands
| Compound |
Type |
Affinity |
Research Status |
| SB-699551 |
Antagonist |
5-HT5A selective |
Research tool |
| SB-699551-2 |
Antagonist |
5-HT5A selective |
Preclinical |
| AS-2038920 |
Agonist |
5-HT5A selective |
Research |
| A-843277 |
Antagonist |
5-HT5A |
Tool compound |
- Limited understanding of physiological functions
- Few selective ligands available
- Species differences in receptor pharmacology
- Brain penetration requirements
- Receptor dimerization complexity
- 5-HT5A expression reduced in AD hippocampus
- Amyloid-beta affects 5-HT5 signaling
- Cognitive decline correlates with receptor loss
- Therapeutic potential for cognition enhancement
- 5-HT5 receptors on serotonergic terminals
- Interaction with dopaminergic system
- L-DOPA-induced dyskinesias may involve 5-HT5
- Sleep disorders in PD benefit from modulation
- 5-HT5 expression on immune cells
- Inflammatory modulation possible
- Myelin repair research ongoing
- Fatigue in MS may involve serotonergic system
| Method |
Application |
| Radioligand binding |
Receptor density measurement |
| Immunohistochemistry |
Protein localization |
| In situ hybridization |
mRNA distribution |
| Knockout mice |
Functional studies |
| Conditional knockout |
Cell-type specific deletion |
| RNA sequencing |
Expression profiling |
- HTR5A-/- mice: Constitutive knockout
- HTR5B-/- mice: Subtype-specific deletion
- Double knockout: Combined deletion
- Humanized mice: Translational research
- Physiological functions remain poorly understood
- Therapeutic indications not established
- Receptor heteromers not characterized
- Signal transduction bias not defined
- Selective tool compounds development
- Physiological role elucidation
- Disease involvement characterization
- Clinical trials for novel indications
- Nelson DL. 5-HT5 receptors. Curr Drug Targets CNS Neurol Disord. 2004 Aug;3(4):277-84.
- Sommer B. 5-HT5 receptors. Trends Pharmacol Sci. 2006 Apr;27(4):200-4.
- Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999 Aug;38(8):1083-52.
- Hamon M, et al. The 5-HT5 receptors: Subtype identification, pharmacological properties, and central nervous system functions. Serotonin. 1990:161-75.
- Deehan JC Jr, et al. Distribution of 5-HT5 receptors in the mouse brain. Neuroscience. 2018 Jul;380:74-89.
- Francken BJ, et al. Pharmacological characterization of the human 5-HT5A receptor in insect cells. J Recept Signal Transduct Res. 2001 Jan;21(1):33-47.
- Kushwaha N, et al. Signal transduction pathways of the human 5-HT5A receptor. Eur J Pharmacol. 2006 Aug;546(1-3):11-20.
- Wang CD, et al. 5-HT5A receptor-mediated phosphorylation of extracellular signal-regulated kinases in rat brain. Neurosci Lett. 2002 Oct;327(2):85-8.